ChemoCentryx Inc. (NASDAQ:CCXI) shares traded up 6.3% during trading on Tuesday . The stock traded as high as $5.42 and last traded at $5.23, with a volume of 158,266 shares. The stock had previously closed at $4.92.

Several research analysts have recently commented on the company. Zacks Investment Research downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a report on Monday, May 16th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $11.00 price objective on shares of ChemoCentryx in a report on Tuesday, August 9th. Finally, Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a report on Thursday, May 19th.

The stock’s 50-day moving average price is $4.58 and its 200 day moving average price is $3.85. The firm’s market cap is $251.23 million.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.